| Journal of Hematology, ISSN 1927-1212 print, 1927-1220 online, Open Access |
| Article copyright, the authors; Journal compilation copyright, J Hematol and Elmer Press Inc |
| Journal website http://www.thejh.org |
Original Article
Volume 5, Number 4, December 2016, pages 117-122
The Clinical Course and Prognosis of Patients With Essential Thrombocythemia Treated With Hydroxyurea and Low-Dose Aspirin in an 11-Year Follow-Up
Tables
| High risk | Low risk | |
|---|---|---|
| Platelet count | Platelet count in excess of 1,500 × 109/L | Platelet count less than 1,500 × 109/L |
| Cardiovascular risk factors: smoking, hypertension and hypercholesterolemia, obese | Yes | No |
| Markers of hypercoagulability: factor V Leiden and antiphospholipid antibodies | Yes | No |
| Age | Over 60 years | Under 60 years |
| Past medical history of thrombosis | Yes | No |
| Frequency | Percent | |
|---|---|---|
| Co-morbidities | ||
| Hypertension | 15 | 19.7 |
| Diabetes | 1 | 1.3 |
| Hypertension+ diabetes | 1 | 1.3 |
| Hypothyroidism | 3 | 3.9 |
| Portal hypertension | 1 | 1.3 |
| COPD | 2 | 2.6 |
| No second disease | 53 | 69.7 |
| Total | 76 | 100.0 |
| The main clinical presentation of ET | ||
| Refer with thrombocytosis | 40 | 52.6 |
| Vertigo and headache | 14 | 18.4 |
| Hemorrhage | 7 | 9.2 |
| Thrombosis | 6 | 7.9 |
| Itching | 3 | 3.9 |
| Other (include functional symptom) | 6 | 7.9 |
| Total | 76 | 100.0 |
| No. of patients | Percent | |
|---|---|---|
| Platelets (× 109/L) The mean platelets 818,000 | ||
| 450,000 - 1,000,000/μL | 61 | 80.3 |
| > 1,500,000/μL | 15 | 19.7 |
| Leukocytes The mean white blood cells (9,300) | ||
| > 4,500/μL | 3 | 3.9 |
| 4,500 - 11,000/μL | 59 | 77.6 |
| > 11,000/μL | 14 | 18.4 |
| Hemoglobin (g/dL) Male: 13 - 16 g/dL Female: 12 - 15 g/dL | ||
| < normal | 20 | 26.3 |
| Normal | 53 | 69.7 |
| > normal | 3 | 3.9 |
| Spleen | 10 | 13.2 |
| > 135 mm | ||
| < 135 mm | 66 | 86.8 |
| Thrombosis | Frequency | Percent |
|---|---|---|
| No thrombosis | 68 | 89.5 |
| Portal vein | 2 | 2.6 |
| Lung embolism | 1 | 1.3 |
| Brain | 5 | 6.5 |
| Total | 76 | 100.0 |
| Adverse event | Grade 1 | Grade 2 | Grade 3 | Grade 4 |
|---|---|---|---|---|
| *Grade 1: minimal skin changes or dermatitis (e.g., erythema, edema, or hyperkeratosis) without pain. Grade 2: skin changes (e.g., peeling, blisters, bleeding, edema, or hyperkeratosis) with pain; limiting instrumental ADL. Grade 3: severe skin changes (e.g., peeling, blisters, bleeding, edema, or hyperkeratosis) with pain; limiting self care ADL. **Grade 1: hyperpigmentation covering < 10% BSA; no psychosocial impact. Grade 2: hyperpigmentation covering > 10% BSA; associated psychosocial impact. ***Grade 1 :< LLN - 3,000/mm3; Grade 2: > 2000 - < 3000/mm3; Grade 3: > 1,000 - < 2,000/mm3; Grade 4: < 1,000/mm3. ****Grade 1: < LLN - 75,000/mm3; Grade 2: > 50,000 - < 75,000/mm3; Grade 3: > 10,000 - <50,000/mm3; Grade 4: < 10,000/mm3. *****Hemoglobin (Hgb). Grade 1: < LLN - 10.0 g/dL; Grade 2: 8.0 - <10.0 g/dL; Grade 3: 6.5 - < 8.0 g/dL; Grade 4: < 6.5 g/dL. ******ANC < 1,000/mm3 with a single temperature of > 38.3 °C (101 °F) or a sustained temperature of ≥ 38 °C (100.4 °F) for more than 1 h. Life-threatening consequences; urgent intervention indicated. | ||||
| Palmar-plantar erythrodysesthesia syndrome* | 1 | 1 | 0 | - |
| Skin hyperpigmentation** | 1 | 0 | - | - |
| Leukocytes (total WBC), mL*** | 21 | 0 | 0 | 0 |
| Platelets, × 103/mL**** | 11 | 1 | 0 | 0 |
| Hb, g/dL****** | 26 | 0 | 0 | 0 |
| Febrile neutropenia****** | 0 | 0 | 0 | 0 |
| Hepatic toxicity | 0 | 0 | 0 | 0 |
| Renal toxicity | 0 | 0 | 0 | 0 |
| Leukemia secondary to oncology hemotherapy | - | - | - | 0 |